关键词: 食管胃结合部腺癌, 外科治疗, 新辅助治疗, 综合治疗

Abstract: The application of perioperative multimodal therapy in the field of adenocarcinoma of the esophagogastric junction (AEG) remains in the exploratory stage. Neoadjuvant chemoradiotherapy has shown potential in enhancing pathological response (PR) rates and surgical resection rates to some extent, yet its survival benefit compared to neoadjuvant chemotherapy alone may not be significant. The role of immunotherapy in the neoadjuvant setting for AEG primarily manifests in improving PR rates, but it has not exhibited superior outcomes in terms of survival. Future research efforts should focus on identifying new targets for targeted therapy, exploring mechanisms of resistance to targeted therapies, and selecting specific patient populations that may benefit from such treatments. In terms of surgical interventions, total gastrectomy remains the preferred approach for AEG and some upper gastric cancers. For early-stage and apart of advanced-stage AEG patients, proximal gastrectomy can preserve part of the stomach’s structure and function; however, there is substantial controversy regarding the choice and efficacy of gastrointestinal reconstruction methods. Based on current research evidence, it is not yet recommended to routinely administer immunotherapy combined with chemotherapy as a postoperative adjuvant treatment for AEG patients. Larger, high-quality clinical studies are awaited to provide further proof.

Key words: esophagogastric junction adenocarcinoma, surgical treatment, neoadjuvant therapy, multimodal therapy